Screener Rankings Investors Themes Guide

Loading...

Explore

Screener
Rankings
Themes
Compare
Investors

Lists

Dividend Aristocrats
Dividend Kings
High ROE
Low Debt

Learn

Guide
How to Analyze a Stock
Insider Trading
Institutional Ownership
Dividend Investing
Return on Equity
Free Cash Flow
Methodology
About

Sectors

Information Technology
Health Care
Financials
Consumer Discretionary
Consumer Staples
Communication Services
Industrials
Energy
Real Estate
Materials
Utilities

Data sourced from SEC EDGAR. All financial data is public domain under U.S. government works doctrine.

This is not investment advice. Nothing on this site constitutes financial, investment, or trading advice. Always do your own research and consult a qualified financial advisor before making investment decisions.

© 2026 Billiver.Privacy Policy Terms of Service Cookie Policy

Home
/
ArriVent BioPharma, Inc.
/
Financials

Company / Financials

ArriVent BioPharma, Inc. Financials

FY2023-FY2024 · Annual data · Source: SEC filings

At a glance

Latest annual filing available

Revenue

-

FY2024

Net Income

-$80.5M

FY2024 · -16.1% YoY

Profit Margin

-

FY2024 · net income / revenue

ROE

-31.2%

FY2024 · return on equity

Total Assets

$274.9M

FY2024

Total Debt

-

FY2024

Equity

$257.7M

FY2024

ROA

-29.3%

FY2024 · return on assets

New to financial statements? Read the quick guide.Open

Statement paths

Income StatementRevenue, expenses, margins, and profit.View Balance SheetAssets, debt, liabilities, and equity.View Cash Flow StatementCash generated, reinvested, and returned.View

Financial highlights

Key Data Points

Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
High earnings quality (cash-backed earnings)

Data sourced from SEC EDGAR filings. Not investment advice.

Metric history

Net Income HistoryProfit after all expenses and taxes-$80.5M-16.1% YoY Operating Income HistoryProfit from core business operations before interest and taxes-$94.3M-26.4% YoY SG&A Expense HistorySelling, general, and administrative expenses$15.3M+57.7% YoY R&D Expense HistoryResearch and development spending$79.0M+21.8% YoY EPS (Basic) HistoryBasic earnings per share-$2.56+92.1% YoY EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.56+92.1% YoY Shares Outstanding HistoryWeighted average diluted shares outstanding31.5M+1369.9% YoY Total Assets HistoryTotal value of all assets owned$274.9M+68.6% YoY Shareholders' Equity HistoryTotal assets minus total liabilities$257.7M+268.2% YoY Cash & Equivalents HistoryCash and short-term liquid investments$74.3M-50.6% YoY

Continue your research

Income StatementRevenue, expenses, margins, and profit.View Balance SheetAssets, debt, liabilities, and equity.View Cash Flow StatementCash generated, reinvested, and returned.View Financial RatiosMargin, return, leverage, and DuPont context.View Piotroski F-ScoreNine checks for profitability, leverage, and efficiency.View Altman Z-ScoreA bankruptcy-risk model built from financial statements.View

Data basis

2 annual filings shown

Primary company stock selected

SEC annual filings used as source

Financial data is for research and education. This is not investment advice.

Back to ArriVent BioPharma, Inc. overview

Data Sources

SEC 10-K Annual Filings

FY2024· Updated Feb 28, 2026

System data refreshed: Jul 2, 2026

For informational purposes only. Not investment advice. Past performance is not indicative of future results. Data sourced from SEC EDGAR filings. Consult a qualified financial advisor before making investment decisions.